^
Association details:
| Biomarker: | BRAF G466V |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Excerpt:
...patient with metastatic colorectal cancer with BRAF (G466V)...Treatment with the anti-EGFR antibody panitumumab and irinotecan caused tumour regression...PDXs were sensitive to cetuximab treatment with complete regression of the tumour and were insensitive to vemurafenib, whereas trametinib was able to delay tumour growth,
DOI:
10.1038/nature23291
Trial ID:
